Ketamine for rapid reduction of suicidal ideation: A randomized controlled trial

Psychological Medicine

Volumn 45, Issue 16, 2015, Pages 3571-3580

  Murrough, J W ^a   Soleimani, L ^a   Dewilde, K E ^a   Collins, K A ^a   Lapidus, K A ^b   Iacoviello, B M ^a   Lener, M ^a   Kautz, M ^a   Kim, J ^c   Stern, J B ^d   Price, R B ^e   Perez, A M ^a   Brallier, J W ^a   Rodriguez, G J ^a   Goodman, W K ^a   Iosifescu, D V ^a   Charney, D S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; glutamate; ketamine; suicide; treatment

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; KETAMINE;

ADULT; BIPOLAR DISORDER; CONTROLLED STUDY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; STRESS DISORDERS, POST-TRAUMATIC; SUICIDAL IDEATION; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; STRESS DISORDERS, POST-TRAUMATIC; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 84945478974     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291715001506     Document Type: Article

References (50)

1. Aleman A, Denys D (2014). Mental health: a road map for suicide research and prevention. Nature 509, 421-423.
2. Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsche NE, Ameli R, Furey ML, Zarate CA Jr. (2014). Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. Journal of Psychiatric Research 58, 161-166.
3. Barbui C, Esposito E, Cipriani A (2009). Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal 180, 291-297.
4. Beck AT, Steer RA, Ranieri WF (1988). Scale for Suicide Ideation: psychometric properties of a self-report version. Journal of Clinical Psychology 44, 499-505.
5. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). Journal of Traumatic Stress 11, 125-136.
6. Brent DA, Melhem N (2008). Familial transmission of suicidal behavior. Psychiatric Clinics of North America 31, 157-177.
7. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM (2003). Psychological autopsy studies of suicide: a systematic review. Psychological Medicine 33, 395-405.
8. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr., Akil H, Watson SJ, Jones EG (2005). Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proceedings of the National Academy of Sciences USA 102, 15653-15658.
9. Cipriani A, Hawton K, Stockton S, Geddes JR (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. British Medical Journal (Clinical Research Edition) 346, f3646.
10. Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J (2006). Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database of Systematic Reviews 18(4). Art. no. CD003492.
11. Crosby AE, Han B, Ortega LA, Parks SE, Gfroerer J, Centers for Disease Control and Prevention (CDC) (2011). Suicidal thoughts and behaviors among adults aged 518 years-United States, 2008-2009. Morbidity and Mortality Weekly Report. Surveillance Summaries 60, 1-22.
12. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr. (2010a). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 71, 1605-1611.
13. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G,Machado-Vieira R, Manji HK, Zarate CA Jr. (2010b). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 67, 793-802.
14. Duman RS, Aghajanian GK (2012). Synaptic dysfunction in depression: potential therapeutic targets. Science (New York, NY) 338, 68-72.
15. Dwivedi Y, Mondal AC, Rizavi HS, Conley RR (2005). Suicide brain is associated with decreased expression of neurotrophins. Biological Psychiatry 58, 315-324.
16. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Traskman-Bendz L, Guillemin GJ, Brundin L (2013). Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38, 743-752.
17. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B (2009). Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Progress in Neuro-psychopharmacology & Biological Psychiatry 33, 70-75.
18. Garakani A, Martinez JM, Yehuda R, Gorman JM (2013). Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. Journal of Affective Disorders 146, 262-265.
19. Griffiths JJ, Zarate CA Jr., Rasimas JJ (2014). Existing and novel biological therapeutics in suicide prevention. American Journal of Preventive Medicine 47, S195-S203.
20. J. W. Murrough, Kang HJ, Kim JM, Lee JY, Kim SY, Bae KY, Kim SW, Shin IS, Kim HR, Shin MG, Yoon JS, et al. (2013). BDNF promoter methylation and suicidal behavior in depressive patients. Journal of Affective Disorders 151, 679-685.
21. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW (2014). A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry 76, 970-976.
22. Larkin GL, Beautrais AL (2011). A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology 14, 1127-1131.
23. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (New York, NY) 329, 959-964.
24. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Bjorkqvist M, Traskman-Bendz L, Brundin L (2009). Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological Psychiatry 66, 287-292.
25. Mann JJ (2003). Neurobiology of suicidal behaviour. Nature Reviews Neuroscience 4, 819-828.
26. Mann JJ (2005). The medical management of depression. New England Journal of Medicine 353, 1819-1834.
27. Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Takahashi Y, Varnik A, Wasserman D, Yip P, Hendin H (2005). Suicide prevention strategies: a systematic review. Journal of the American Medical Association 294, 2064-2074.
28. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012). Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26, 189-204.
29. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S, International Suicide Prevention Trial Study Group (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82-91.
30. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
31. Murrough JW (2012). Ketamine as a novel antidepressant: from synapse to behavior. Clinical Pharmacology and Therapeutics 91, 303-309.
32. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013a). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry 170, 1134-1142.
33. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aanhet Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2013b). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry 74, 250-256.
34. Overall JE, Gorham DR, Shawver JR (1961). Basic dimensions of change in the symptomatology of chronic schizophrenics. Journal of Abnormal and Social Psychology 63, 597-602.
35. Posner K, Oquendo MA, Gould M, Stanley B, Davies M (2007). Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. American Journal of Psychiatry 164, 1035-1043.
36. Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ (2014). Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depression and Anxiety 31, 335-343.
37. Price RB, Nock MK, Charney DS, Mathew SJ (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry 66, 522-526.
38. Rockett IR, Regier MD, Kapusta ND, Coben JH, Miller TR, Hanzlick RL, Todd KH, SattinRW, Kennedy LW, Kleinig J, Smith GS (2012). Leading causes of unintentional and intentional injury mortality: United States, 2000-2009. American Journal of Public Health 102, e84-e92.
39. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G, STAR, D Investigators Group (2004). Sequenced treatment alternatives to relieve depression (STAR, D): rationale and design. Controlled Clinical Trials 25, 119-142.
40. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573-583.
41. Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, Rehal S, Klempan T, Gratton A, Benkelfat C, Rouleau GA, Mechawar N, Turecki G (2009). Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS ONE 4, e6585.
42. Serafini G, Pompili M, Innamorati M, Dwivedi Y, Brahmachari G, Girardi P (2013). Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. Current Pharmaceutical Design 19, 1898-1922.
43. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 (Suppl. 20), 22-33; quiz 34-57.
44. Sowa-Kucma M, Szewczyk B, Sadlik K, Piekoszewski W, Trela F, Opoka W, Poleszak E, Pilc A, Nowak G (2013). Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims. Journal of Affective Disorders 151, 924-931.
45. Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, Nierenberg AA, Gaynes BN, Husain MM, Luther JF, Zisook S, Rush AJ (2011a). Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. Journal of Clinical Psychiatry 72, 757-764.
46. Trivedi MH, Wisniewski SR, Morris DW, Fava M, Kurian BT, Gollan JK, Nierenberg AA, Warden D, Gaynes BN, Luther JF, Rush AJ (2011b). Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. Journal of Clinical Psychiatry 72, 765-774.
47. Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW (2014). Ketamine safety and tolerability in clinical trials for treatment-resistant depression. Journal of Clinical Psychiatry 76, 247-252.
48. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429-435.
49. Zarate CA Jr., Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biological Psychiatry 71, 939-946.
50. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856-864.